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Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression
programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/
ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive
sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a
multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition
of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo.
Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential
oncogenic pathways in MPNST cells, including the Wnt/β-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge
on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and
dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.

Introduction

Malignant peripheral nerve sheath tumors (MPNSTs) are highly
aggressive sarcomas with a strong metastatic potential, usually
to the lung (1). MPNST patients are largely refractory to current
treatments that include radical surgical resection and/or radiaAuthorship note: MPI, EPA, and MIL contributed equally to this work. MVR and AW
are co–senior authors.
Conflict of interest: The authors have declared that no conflict of interest exists.
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tion and chemotherapy, and have very poor 5-year survival rates
ranging between 15% and 50% (1). Half of MPNST cases arise
in the context of neurofibromatosis type 1 syndrome (NF1), and
these tumors are a leading cause of death in NF1 patients. In
NF1, loss of the NF1 tumor suppressor gene that encodes the Ras
GTPase-activating protein neurofibromin leads to the development of benign neurofibromas that are located on the skin (cutaneous neurofibromas) or can be deep-seated in large peripheral
nerves (plexiform neurofibromas). Plexiform neurofibromas can
transform into MPNSTs, which can also occur spontaneously
(sporadic MPNSTs) or after radiotherapy. There is general acceptance that cells of the Schwann cell lineage are the crucial neoplastic cells in MPNSTs (1, 2).
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Figure 1. HuR is upregulated in human MPNSTs. (A and B) HuR mRNA levels in nerves, neurofibromas, and MPNSTs from patients (A) and mouse models
(B) from the Jessen cohort (GSE41747) (7). (C) Representative immunohistochemistry micrographs of endogenous HuR protein levels (brown) in a tissue
microarray panel of human nerves (n = 7), benign neurofibromas (n = 76), and MPNSTs (n = 109) (15). Score 0, low HuR staining; 1, intermediate staining; 2,
high HuR staining. Scale bar: 50 μm. (D–G) Western blot and quantitative reverse transcriptase PCR (RT-qPCR) analysis of HuR levels in a panel of human
nerves (n = 5), benign neurofibromas (n = 12), and MPNSTs (n = 15) obtained from Stanmore Musculoskeletal Biobank. (D) Representative immunoblots
showing total and cytoplasmic HuR levels in a selection of samples. (E and F) Graphs representing densitometry analysis of total HuR protein levels,
corrected for Ponceau red signals (E), and cytoplasmic HuR protein levels, corrected for Ponceau red signals (F). (G) HuR mRNA levels as measured by RT-
qPCR analysis. Data are presented as mean ± SEM (A and B) or median with interquartile range (E–G); 1-way ANOVA with Tukey’s multiple-comparisons
test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. The number of samples (n) per group is indicated.

A number of mutations that drive MPNST pathogenesis have
been identified, with a surprising degree of overlap in NF1-associated and sporadic forms. These include molecular variants of the
NF1 tumor suppressor gene that are present in all NF1 patients,
and in a majority of sporadic and radiation-induced MPNSTs (2,
3). Other ancillary, yet essential, cancer-driving genetic aberrations include loss of the genes CDKN2A, TP53, RB, or PTEN, or
the genes encoding the PRC2 components SUZ12 or EED, and
amplification of PDGFRA, EGFR, or MET (4, 5). In addition,
recent studies have shown that activation of multiple signaling
pathways, including the PI3K/AKT/mTOR, RAS/RAF-MEKERK, Wnt/β-catenin, and HIPPO-YAP/TAZ pathways, and other
less ubiquitous molecular alterations involving aurora kinases
and transcription factors (TFs) such as SOX9, also contribute to
MPNST pathogenesis (1, 3, 6).
Gene dysregulation is a hallmark of cancer cells. Genetic
alterations in cancer cells invariably lead to a global remodeling
of their transcriptome, allowing them to acquire advanced functional capabilities for survival, proliferation, and dissemination.
MPNSTs have a unique transcriptomic signature that is clearly distinct from normal or even neurofibroma-derived primary Schwann
cells or tumors (7, 8), and strongly associated with key Schwann
cell developmental programs, including control of survival and

proliferation. Targeting dysregulated gene expression programs
in cancers has emerged as a promising therapeutic strategy, and
there is an intense focus on identifying the key molecular regulators that govern these programs (9, 10). In particular, RNA-binding
proteins (RBPs) are increasingly recognized as attractive targets
because of their ability to regulate the type and abundance of hundreds of transcripts by modulating every aspect of their post-transcriptional life — splicing, transport, localization, translation, stabilization, and decay. Furthermore, each RBP can bind to multiple
overlapping groups of functionally related RNAs, forming “RNA
regulons” that control many biological functions (11).
We have previously shown that the ubiquitously expressed RBP
HuR/ELAVL1 was highly expressed in immature Schwann cells,
a stage of development characterized by a peak in Schwann cell
proliferation and apoptosis. We found that HuR was bound to and
regulated several key mRNAs, coordinately regulating them at the
post-transcriptional level (12). Subsequently, as immature Schwann
cells differentiated, we found that they lost expression of HuR, and
the production of HuR targets encoding proliferation and apoptosis proteins was downregulated. Notably, many of the HuR targets
in immature Schwann cells become re-expressed in MPNSTs, and
the encoded proteins play key roles in tumor growth, as shown for
SOX9 (8) and BRD4 (13). HuR is frequently upregulated in different
jci.org   Volume 130   Number 7   July 2020
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Figure 2. HuR is bound to key targets in human MPNSTs. (A) Volcano plots show enrichment of transcripts most significantly bound to HuR compared
with control IgG in neurofibromas (left) (n = 8) and MPNSTs (right) (n = 12) obtained from Stanmore Musculoskeletal Biobank. Red or blue dots, fold change
>1.5; adjusted P value < 0.05. Venn diagram shows overlap between putative HuR mRNA targets from neurofibromas and MPNSTs. (B) GSEA analysis of
putative HuR mRNA targets in MPNSTs for MSigDB hallmarks. The top 20 gene sets (FDR iQ values < 0.1) are plotted relative to normalized enrichment
score (NES). Circles denote the number of enriched genes in each category. (C and D) GSEA plots of HuR IP and control IgG IP for key cancer traits (C) and
oncogenic pathways (D) in MPNSTs.

cancer types (14), leading us to hypothesize that HuR could become
re-expressed in MPNSTs, where it would have a key role in driving
the dysregulated transcriptomic programs. Here, we present evidence that HuR is potently tumorigenic in MPNSTs and that suppressing HuR expression reduces tumor growth and metastasis. We
propose that the malignant influence of HuR is linked to enhancing
multiple key oncogenic programs operating in MPNST cells.

Results

HuR is upregulated in human MPNSTs. To explore the potential role
of HuR in Schwann cell cancers, we searched a publicly available
expression data set (Gene Expression Omnibus [GEO] GSE41747)
(7) and found that HuR/ELAVL1 mRNA levels were significantly
upregulated in MPNSTs, both in patients and in mouse samples
(Figure 1, A and B). Next, we analyzed HuR protein abundance by
immunohistochemistry in a human tissue microarray panel comprising normal nerves (n = 7), benign neurofibromas (n = 76), and
MPNSTs (n = 109) (15) and, similarly, found a strong upregulation
of HuR protein expression in MPNSTs (Figure 1C). Finally, we validated these results by examining HuR protein and mRNA expression in an independent cohort of frozen human normal nerves
(n = 5), neurofibromas (n = 12), and MPNSTs (n = 15), obtained
3850
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from the Stanmore Musculoskeletal Biobank (United Kingdom).
We confirmed that total HuR protein levels were significantly elevated in the MPNST samples (Figure 1, D and E). We also examined cytoplasmic HuR levels, since HuR export from the nucleus
to the cytoplasm is linked to its function as a post-transcriptional
regulator of target mRNAs (16). As shown (Figure 1, D and F), cytoplasmic HuR levels were higher in MPNST samples. HuR mRNA
levels were also higher in these samples (Figure 1G).
We did not find significant differences in the abundance of
HuR mRNA or protein when comparing dermal neurofibromas
and plexiform neurofibromas from our frozen cancer panel (Supplemental Figure 1A; supplemental material available online with
this article; https://doi.org/10.1172/JCI130379DS1; see complete
unedited blots in the supplemental material), nor were there
differences in HuR mRNA levels in publicly available data sets
(Supplemental Figure 1, B and C). Notably, we also did not find
significant differences in the levels of HuR mRNA or protein when
comparing NF1-derived and sporadic MPNSTs (Supplemental
Figure 1, D and E).
The high abundance and cytoplasmic localization of HuR
point to a potentially important role in both sporadic and NF1derived MPNSTs.

The Journal of Clinical Investigation  
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Figure 3. HuR promotes MPNST cell growth in vivo. (A and B) Constitutive HuR silencing prevents tumor formation in vivo. (A) Schematic representation
of xenotransplantation experiments. (B) Representative pictures of tumors from nude mice injected with shCtrl or shHuR#1 STS-26T MPNST cells 5 weeks
after transplant (n = 5) for each condition. Scale bar: 5 mm. (C–F) Inducible HuR silencing promotes tumor regression in vivo. (C) Schematic representation
of xenotransplantation experiments using inducible HuR-silencing strategy. (D) Representative pictures of tumors from nude mice injected with sh iCtrl
or sh iHuR STS-26T MPNST cells on left and right flank, respectively, at 20 days after injection (day 20) and 10 days later (day 30), with (+ Dox) or without
doxycycline diet (– Dox). (E) Waterfall plot showing change in tumor volume (represented as log2 fold change) of individual tumors formed at 20 days after
transplant and after 10 days with or without doxycycline treatment for each of 4 groups of mice. sh iCtrl (–Dox) n = 7; sh iCtrl (+Dox) n = 7; sh iHuR (–Dox)
n = 7; sh iHuR (+Dox) n = 7. (F) Graph showing weight of excised tumors for the 4 groups of mice. Each data point represents 1 mouse; 1-way ANOVA with
Tukey’s multiple-comparisons test. **P < 0.01; ***P < 0.001; ****P < 0.0001.

RIP-Chip identifies HuR mRNA targets associated with key
cancer traits. To examine the biological significance of the high
HuR levels in MPNSTs, we analyzed HuR-associated mRNAs on
a genome-wide scale by ribonucleoprotein immunoprecipitation
(RIP) under conditions that preserve endogenous RNA-protein
interactions, followed by microarray detection of bound mRNAs
(RIP-Chip) (17, 18). Notably, RIP preferentially enriches for
the stably bound subsets of putative mRNA targets rather than
transient targets that might be detected by ribonucleoprotein
cross-linking. This favors the identification of targets forming
part of functional complexes that lead to mRNA target stabilization and increased translation (19).
RIP analysis was performed using an anti-HuR antibody or control anti-IgG antibody and cytoplasmic extracts from human neurofibroma (n = 8) and MPNST (n = 12) samples from the aforementioned
frozen cancer panel, and the isolated RNA was identified by microarray analysis (Supplemental Figure 2, A and B). Background mRNAs
identified in side-by-side control immunoprecipitation reactions
using mouse anti-IgG antibody were subtracted to identify bona fide
HuR-interacting mRNAs. We found that HuR was specifically bound

to 71 and 276 mRNAs in neurofibroma and MPNST samples, respectively (Figure 2A and Supplemental Tables 1 and 2). The large majority of neurofibroma targets (60 of 71; 85%) were also associated with
HuR in the MPNST samples, whereas 216 HuR-bound transcripts
were exclusively expressed in MPNST samples (Figure 2A), in line
with the high HuR expression in MPNST samples, and supporting a
role for HuR in malignant Schwann cell tumors.
To identify molecular pathways associated with HuR-bound
transcripts in MPNSTs, we performed gene set enrichment analysis
(GSEA) using Molecular Signatures Database (MSigDB) hallmarks
(20). GSEA revealed significant enrichment of signatures associated with oncogenic traits including cell cycle progression, epithelial-mesenchymal transition, and angiogenesis (21), as well as signatures for the key oncogenic TFs MYC and E2F (refs. 22, 23, and
Figure 2B). In addition, key signaling pathways in MPNSTs, including the Wnt/β-catenin, PI3K/AKT/mTOR, and RAS pathways (1, 2),
were also enriched (Figure 2, B–D, and Supplemental Table 3).
Together, these data point to a potentially important biological function of HuR in MPNSTs, possibly regulating key signaling
pathways that control oncogenic traits in these malignant tumors.
jci.org   Volume 130   Number 7   July 2020
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Figure 4. HuR promotes MPNST metastasis in vivo. (A–C) Constitutive HuR silencing prevents lung metastasis of STS-26T MPNST cells. (A) Schematic
representation of lung metastasis experiments. shCtrl (n = 6) or shHuR#1-expressing (n = 7) STS-26T MPNST cells were injected in the tail vein of nude
mice, and lung architecture analyzed by H&E staining 4 weeks later. Representative pictures of lung histology are shown. Scale bar: 2 mm. (B and C)
Number of lung metastases (B) and lung metastatic area, expressed as a percentage of total lung area (C), were quantified by H&E histology. (D–F) Inducible HuR silencing prevents growth of established lung metastatic nodules. (D) Schematic representation of experiments. sh iCtrl or sh iHuR–expressing
STS-26T MPNST cells were injected in the tail vein of nude mice. A group of mice (n = 3 for each condition) was sacrificed at 2 weeks (W2) to analyze basal
formation of lung metastases, and the rest fed with normal diet (–Dox) or doxycycline diet to induce expression of shRNAs (+Dox) for a further 4 weeks
before analysis of lung histology by H&E staining. Representative pictures of lung histology for the following groups are shown: sh iCtrl with normal diet
(sh iCtrl; –Dox) n = 5; sh iCtrl with doxycycline diet (sh iCtrl; +Dox) n = 5, sh iHuR with normal diet (sh iHuR; –Dox) n = 5, sh iHuR with doxycycline diet (sh
iHuR; +Dox) n = 5. Scale bar: 2 mm. (E and F) Number of lung metastases (E) and lung metastatic area, expressed as a percentage of total lung area (F),
were quantified. Each data point represents 1 mouse. Data are presented as mean ± SEM; 2-tailed unpaired Mann-Whitney U test (B and C); 1-way ANOVA
with Holm-Šidák multiple-comparisons test (E and F). *P < 0.05; **P < 0.01.

HuR promotes MPNST cell growth in vitro and in vivo. To characterize the functional importance of HuR, we first evaluated its abundance in established MPNST cell lines. Using a publicly available
expression data set (GEO GSE14038) (8), we found that HuR mRNA
levels were significantly upregulated in MPNST cell lines compared
with neurofibroma-derived Schwann cells (Supplemental Figure 3A). Furthermore, higher HuR mRNA and protein levels were
observed in 4 commonly used MPNST cell lines — ST88-14, 90-8,
S462, and STS-26T — compared with freshly isolated Schwann cells
derived from human nerves (Supplemental Figure 3, B and C).
We then silenced HuR in these 4 MPNST cell lines by lentiviral
delivery of 2 distinct HuR-specific shRNAs and examined cellular growth. Three of the cell lines (ST88-14, 90-8, and S462) were
derived from NF1 patients with confirmed loss of heterozygosity
at the NF1 locus for all 3 cell lines; the 90-8 cell line additionally showed a known microdeletion of NF1, whereas the sporadic
MPNST line STS-26T had no mutations detected in the 60 exons
of the NF1 gene. These MPNST cell lines share a common gene
expression profile distinct from that of normal Schwann cells,
3852
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although they differ in proliferation rates and in expression of cell
cycle proteins (24). Both constitutively expressed shRNAs reduced
HuR levels efficiently, and suppressed cell growth, as shown by
measurement of ATP levels and by direct cell counts in all 4 cell
lines (Supplemental Figure 3, D–F). Furthermore, HuR silencing
significantly reduced the clonogenic and anchorage-independent
growth capacity of all 4 cell lines (Supplemental Figure 4, A–C).
Since the in vitro consequences of HuR perturbation were
shared by all MPNST cell lines, we selected as representative
STS-26T for in vivo validation. STS-26T cells in which HuR levels were normal or reduced by silencing were implanted subcutaneously in immunodeficient mice. Subsequent analysis revealed
that whereas control cells efficiently formed tumors (5/5), tumor
formation was completely abolished in HuR-silenced cells (0/5)
(Figure 3, A and B).
Next, we examined the effects of HuR depletion on the
growth of already established tumors. To this end, we used a doxycycline-inducible lentiviral shRNA system targeting HuR. STS26T cells expressing pTRIPZ-shControl (sh iCtrl) or pTRIPZ-

The Journal of Clinical Investigation  
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Figure 5. Pharmacological inhibition of HuR blocks MPNST cell growth and metastasis in vitro and in vivo. (A and B) Pharmacological inhibition of HuR
activity leads to a reduction in cell growth in MPNST cell lines ST88-14 and STS-26T, as determined by ATP luminescence, counts of cell numbers, clonogenic
assays (foci), and anchorage-independent growth using soft agar assays. Graphs represent absorbance of crystal violet–stained colonies for clonogenic assays
and number of colonies in soft agar assays. Data are normalized to DMSO-treated and are presented as mean ± SEM. Each data point represents 1 independent
experiment; 1-way ANOVA with Tukey’s multiple-comparisons test. (C–E) Pharmacological inhibition of HuR activity by MS-444 promotes tumor regression in
vivo. (C) Pictures of tumors from nude mice injected with STS-26T MPNST cells after vehicle or MS-444 treatment. Scale bar: 10 mm. (D) Graph showing weight
of excised tumors for both groups of mice. (E) Waterfall plot showing change in tumor volume (represented as log2 fold change) of individual tumors formed at
20 days after transplant, and after 10 days with pharmacological inhibition. Each data point represents 1 mouse. Data are presented as mean ± SEM; 2-tailed
unpaired Mann-Whitney U test. (F–H) Pharmacological inhibition of HuR activity by MS-444 prevents growth of established lung metastatic nodules in vivo.
(F) Representative pictures of lung histology from nude mice injected with STS-26T MPNST cells after vehicle or MS-444 treatment. Scale bar: 5 mm. (G and H)
Number of lung metastases (G) and lung metastatic area, expressed as a percentage of total lung area (H), were quantified. Each data point represents 1 mouse.
Data are presented as mean ± SEM; 2-tailed unpaired Mann-Whitney U test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

shHuR (sh iHuR) were injected subcutaneously in the left and
right flanks of immunodeficient mice, respectively, and tumors
were allowed to form for about 20 days until they were palpable
(~100 mm3 average). Mice were randomly assigned to standard
chow diet or doxycycline diet for a period of 10 days, whereupon
mice were sacrificed and tumors extracted (Figure 3C). Remark-

ably, induction of HuR shRNA by doxycycline treatment severely
blunted tumor growth, and even led to visible tumor regression
(Figure 3D). Tumor regression was observed in all mice following
HuR depletion, and on average tumors shrank by 40% (Figure 3E)
and weighed significantly less than control tumors (Figure 3F).
HuR-depleted cells formed smaller tumors, and the efficiency of
jci.org   Volume 130   Number 7   July 2020
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Figure 6. RNA-Seq reveals that HuR controls key oncogenic pathways in MPNSTs. (A) Heatmap representation of differentially expressed genes between
shCtrl (n = 3) or shHuR#1-expressing (n = 3) ST88-14 MPNST cells (fold change >2; adjusted P value < 0.05). (B) Volcano plot of transcriptome profiles
between shCtrl (n = 3) and shHuR#1-expressing (n = 3) ST88-14 MPNST cells. Red and blue dots represent genes significantly upregulated and downregulated, respectively, in shHuR#1-expressing cells (fold change >2; adjusted P value < 0.05). (C) GSEA analysis of shCtrl and shHuR#1-expressing ST88-14
MPNST cells for MSigDB oncogenic signatures. Gene sets with FDR Q values less than 0.25 are plotted relative to normalized enrichment score (NES).
Categories with negative (left) and positive (right) NES are down- or upregulated, respectively, in shCtrl cells. Circles denote the number of enriched genes
in each category, and colors represent FDR Q values as indicated.

HuR silencing was confirmed in those tumors by Western blotting analysis (Supplemental Figure 5, A and B). Notably, tumors
arising from sh iHuR cells without doxycycline treatment were
indistinguishable in all parameters from tumors arising from sh
iCtrl cells with or without doxycycline treatment, supporting the
efficiency and specificity of the inducible system used.
We also documented a marked reduction in the proliferation
marker Ki67 and a rise in an apoptotic marker, active caspase-3,
in HuR-depleted tumors (Supplemental Figure 5C). We validated these results in the panel of cultured MPNST cell lines, where,
similarly, genetic depletion of HuR in the 4 cell lines potently
reduced cell proliferation as measured by (a) cell cycle analysis
by flow cytometry, which showed a general increase in the percentage of cells in the G1 phase and a decrease in cells in the S and
G2/M phases, consistent with a G1 cell cycle arrest, and (b) BrdU
incorporation (Supplemental Figure 6, A and B). We also found
a marked increase in senescence after HuR silencing in all 4 cell
lines (Supplemental Figure 6C). Detection of annexin V by flow
cytometry indicated a trend toward increased apoptosis in all 4
cell lines after HuR knockdown when cells were cultured under
basal, growth-promoting conditions (10% serum). Exposure to
cellular stress, such as culture of cells under growth-limiting
conditions (2% serum) (13), exaggerated this effect and led to a
marked increase in apoptotic and necrotic cell death after HuR
depletion (Supplemental Figure 6D).
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Together, these data indicate that HuR plays an important
functional role in MPNST cell biology by controlling key features
such as survival, proliferation, and replicative immortality.
HuR promotes MPNST metastasis in vivo. MPNSTs have a high
metastatic potential, and up to 50% of patients develop metastatic disease, usually to the lung, further worsening 5-year survival
rates of patients (1, 25). Yet, metastasis is one of the least understood aspects of MPNSTs. Given the profound antitumor effects
of HuR in MPNST cells, and the identification of epithelial-mesenchymal transition signature as one of the top enriched categories of HuR targets from GSEA analysis (Figure 2, B and C), we
decided to examine whether HuR could be important for MPNST
metastasis, using a surrogate model of lung metastasis. Briefly,
this model measures the ability of cells injected in the lateral tail
vein of immunodeficient mice to survive in circulation, arrest at a
distant organ, extravasate, adapt to growth in the foreign microenvironments of a distant tissue, and grow into metastatic lesions,
recapitulating many of the essential late steps in metastasis (26).
We silenced HuR constitutively in STS-26T cells, an MPNST
cell line that exhibits metastatic tropism to the lung (27), injected
them in the tail vein, and examined metastatic colonization of the
lung 4 weeks later by histology (Figure 4A). Remarkably, very few
metastatic lesions were observed in HuR-depleted cells in contrast
to control cells, which formed numerous and large metastatic foci
(Figure 4, B and C). Next, we used our inducible lentiviral silencing
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Figure 7. HuR regulates the YAP/TAZ pathway in MPNSTs. (A and B) GSEA plots showing enrichment of YAP-conserved signature from Figure 6C (A) and
YAP-activated signature set (36) (B) in shCtrl-infected compared with shHuR#1-infected ST88-14 MPNST cells. (C) RIP-qPCR analysis showing binding of
HuR to YAP1, TEAD1, and TEAD2 in 4 MPNST cell lines (ST88-14, 90-8, S462, and STS-26T). Data are normalized to control IgG IPs and are presented as
mean ± SEM, 2-tailed unpaired Student’s t test; n = 4 MPNST cell lines. (D) Representative Western blots showing a general downregulation of key YAP/
TAZ pathway components after HuR silencing in ST88-14 MPNST cells. Technical duplicates are shown, and similar results were obtained in at least 3 independent experiments. (E) RT-qPCR analysis showing downregulation of YAP/TAZ pathway effector genes (6) after HuR silencing in ST88-14 MPNST cells.
Data are normalized to shCtrl cells and are presented as mean ± SEM. Each data point represents 1 independent experiment; 1-way ANOVA with Tukey’s
multiple-comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001.

system to examine the effect of HuR silencing on the colonization
step of the metastatic process, i.e., the survival of the cells in these
foreign microenvironments during the metastatic process, and the
reactivation of their proliferation programs to form overt metastatic lesions. We injected STS-26T cells expressing pTRIPZ-shControl
(sh iCtrl) or pTRIPZ-shHuR (sh iHuR) in the tail vein, and allowed
them to begin to form metastases for 2 weeks. Mice were randomly assigned to standard chow or doxycycline-containing diet
for 4 weeks, whereupon mice were sacrificed and lungs extracted
for histological analysis (Figure 4D). Induction of HuR shRNA by
doxycycline treatment blocked the conversion of these micro
metastases into the macroscopic neoplastic growth seen in the
control cells with or without doxycycline treatment and in sh iHuR
cells without doxycycline treatment (Figure 4, D–F).
Together, these data support a key role for HuR in MPNST
metastasis, potentially controlling key aspects of the metastatic
process, from the survival of the cells in the bloodstream to their
colonization and proliferation within distant organs.
HuR overexpression in Schwann cells is not sufficient to trigger
oncogenic transformation or dissemination. Since HuR is expressed
at notably higher levels in MPNST compared with Schwann cells
(Figure 1 and Supplemental Figure 3, A–C), we next examined
whether elevating HuR levels in human Schwann cells was sufficient to elicit cell transformation and dissemination.
We ectopically expressed HA-tagged HuR using a doxycycline-inducible lentiviral system (28) in immortalized normal
human Schwann cells (iHSCλ2) (Supplemental Figure 7A), and
found that this led to a small but significant increase in cell growth,

as shown by measurement of ATP levels and by direct cell counts,
and increased the clonogenic and anchorage-independent growth
capacity (Supplemental Figure 7B). However, no major effect
was observed on tumor formation in vivo using mouse xenograft
models (Supplemental Figure 7, C and D). We also did not observe
any major effect on tumor formation after ectopic expression of
HuR in immortalized plexiform neurofibroma–derived human
Schwann cells (ipNF SC). These data suggest that while HuR overexpression promotes proliferation in Schwann cells in culture, it is
not sufficient to induce Schwann cell–derived tumors in mice.
Similarly, we examined metastatic properties using tail vein
injections of control or HuR-overexpressing normal and plexiform neurofibroma-derived human Schwann cell lines. We did
not find any metastatic nodules in the controls of either cell line.
Unexpectedly, we found the presence of small micrometastases in
HuR-overexpressing normal Schwann cell lines (1 of 4) and plexiform human Schwann cell lines (3 of 4) (Supplemental Figure 7E),
although these were far fewer and smaller than after injection of
STS-26T MPNST cell line (Figure 4).
Taken together, our results showed that HuR overexpression in
normal or plexiform neurofibroma Schwann cells was not sufficient
to trigger oncogenic transformation but modestly increased their
metastatic capacity.
Pharmacological inhibition of HuR reduces MPNST growth and
metastasis. Our results demonstrate that elevated HuR levels in
MPNST cells are required for cell growth and metastasis. We next
ascertained whether the inhibition of HuR could be exploited as a
therapeutic strategy using small-molecule HuR inhibitors.
jci.org   Volume 130   Number 7   July 2020
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Figure 8. HuR regulates the RB/E2F pathway in MPNSTs. (A and B) GSEA plots showing enrichment of functionally defined RB (A) and E2F1 (B) signature
set in shCtrl-infected compared with shHuR#1-infected ST88-14 MPNST cells from Figure 6C. (C) Cartoon depicting regulatory components of the RB/E2F
pathway in cell cycle regulation. By interacting with CDKs, cyclins form complexes (cyclin D with CDK4/6 and cyclin E with CDK2) that phosphorylate RB1 (phosphorylated RB1 is inactive). When RB1 is phosphorylated, E2F is released and can transcriptionally activate its target genes, enabling the G1/S transition of cell
cycle. Cyclins can be regulated at the transcription level by the RAS-MEK-ERK pathway and at the translation level by mTOR via S6K and 4EBP1. p21 and p27
can bind to and inhibit cyclin-CDK complexes. (D) RIP-qPCR analysis showing binding of HuR to multiple genes in the RB/E2F pathway in 4 MPNST cell lines
(ST88-14, 90-8, S462, STS-26T). Data are normalized to control IgG IPs and are presented as mean ± SEM, 2-tailed unpaired Student’s t test. (E) Representative Western blots showing a downregulation of several key RB/E2F pathway components after HuR silencing in ST88-14 MPNST cells, in general concordance
with RIP-qPCR data. Technical duplicates are shown, and similar results were obtained in 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.

Pharmacological inhibition of HuR with MS-444, which
inhibits HuR homodimerization to prevent the binding of 3′-UTR
AU-rich elements (29); pyrvinium pamoate, an FDA-approved
anthelmintic drug that blocks HuR nucleocytoplasmic translocation (30); and tanshinone mimic 6N (TM-6N), which inhibits
HuR-RNA complex formation (31), each strongly reduced MPNST
cell growth in culture in ST88-14 and STS-26T cells (Figure 5, A
and B), similarly to what we found through the genetic inhibition
of HuR (Supplemental Figures 3 and 4).
Importantly, i.p. injection with MS-444 (25 mg/kg body
weight; treatment every 48 hours for 10 days) of nude mice bearing already established tumors (formed 20 days after xenograft
transplant of STS-26T cells in flanks) severely blunted tumor
growth, and even led to tumor regression in some cases. In addition, MS-444–treated tumors weighed significantly less than
control tumors (Figure 5, C–E). Remarkably, MS-444 treatment
of nude mice (i.p. injection every 48 hours for 2 weeks; 25 mg/kg
body weight) with established micrometastases that had formed
for 2 weeks after i.v. injection of STS-26T cells also reduced the
conversion of these micrometastases into the macroscopic neoplastic growth, and smaller metastatic areas were measured in
MS-444–treated mice than in vehicle-treated mice (Figure 5, F–H).
Our results show that pharmacological inhibition of HuR
reduces MPNST growth and metastasis, thus highlighting the relevance of HuR as a potential therapeutic target for MPNSTs.
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HuR regulates key oncogenic transcriptional programs. Next, we
sought to define the mechanisms by which HuR exerts such profound
effects on MPNST cells. We silenced HuR expression using lentiviral
vectors expressing constitutive shRNA directed at HuR in the ST8814 cell line, and performed RNA-Seq profiling. We identified distinct
transcriptomic profiles between the control and HuR-depleted cells
(Figure 6A), and differential expression analysis revealed that a notable proportion of the transcriptome in MPNST cells changed significantly. There were similar numbers of significantly upregulated and
downregulated transcripts exhibiting more than 2-fold changes (1563
and 1627, respectively) (Figure 6B and Supplemental Table 4).
GSEA analysis revealed an inhibition of several tumorigenic pathways in MPNST cells by HuR silencing, including the YAP/
TAZ, Wnt/β-catenin, PI3K/AKT/mTOR, and RAS pathways, in
addition to signatures for the key oncogenic TFs MYC and E2F (Figure 6C and Supplemental Tables 5 and 6). There was also significant
overlap between the signature sets we identified by this RNA-Seq
analysis and the RIP-Chip analysis for putative HuR mRNA targets (Figure 2B). These results strongly suggested that HuR could
be affecting MPNST cells by directly regulating these pathways,
several of which have already been established to play key roles in
MPNST tumorigenesis (6, 7, 13, 32–34). We thus set out to examine
the importance of HuR for these pathways.
We first focused on the YAP/TAZ pathway. In an elegant
study, it was recently shown that human MPNSTs exhibit ele-
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Figure 9. HuR activates key oncogenic programs by regulating the Wnt/β-catenin pathway. (A) Compendium of normalized enrichment scores
(NES) of target gene sets associated with the Wnt/β-catenin pathway after GSEA analysis of HuR-silenced ST88-14 MPNST cells (Supplemental
Tables 5 and 6). Notably, there is general positive correlation in the activation of the pathways (highlighted in green) in shCtrl-infected cells. Circles
denotes the number of enriched genes in each category, and colors represent FDR Q values. (B) GSEA plots showing enrichment of a MYC-induced
target gene set in shCtrl cells, and a LEF1-repressed target gene set in shHuR#1-infected cells. (C) RIP-qPCR analysis showing binding of HuR to
CTNNB1 and BCL9 in 4 MPNST cell lines (ST88-14, 90-8, S462, STS-26T). Data are normalized to control IgG IPs and are presented as mean ± SEM,
2-tailed unpaired Student’s t test. (D) Representative Western blots showing a general downregulation of Wnt/β-catenin pathway components,
including key oncogenic downstream regulators, after HuR silencing in ST88-14 MPNST cells. Technical duplicates are shown, and similar results
were obtained in 3 independent experiments. (E) Representative Western blots showing that lentivirus-based expression of constitutively active
β-catenin 4A mutant (harbors alanine substitutions at S33, S37, T41, and S45, preventing its degradation) [pcw107-β-Cat (4A)] partially blocks the
downregulation of the key downstream regulators c-MYC, SOX9, AURKA, and AURKB by HuR silencing (shH#3) in ST88-14 MPNST cells. Technical
duplicates are shown, and similar results were obtained in 3 independent experiments. (F) Ectopic expression of constitutively active β-catenin
4A mutant partially blocks the effects of HuR silencing on cell numbers and ATP levels in ST88-14 MPNST cells. Data are normalized to shCtrl
+ pcw107-EV cells and are presented as mean ± SEM. Each data point represents 1 independent experiment; 1-way ANOVA with Tukey’s multiple-comparisons test. *P < 0.05; **P < 0.01; ****P < 0.001.

vated HIPPO-TAZ/YAP expression, and hyperactivation of
YAP/TAZ in Schwann cells activated an oncogenic program
with development of MPNSTs (6). GSEA analysis of RNA-Seq
data showed that HuR silencing in MPNST cells led to a strong
suppression of a YAP-conserved signature (35) as well as a
functionally validated YAP-activated signature (ref. 36 and Figure 7, A and B). Notably, GSEA also showed a strong negative
correlation of genes regulated by YAP/TAZ hyperactivation
in Schwann cells (6) and genes regulated by HuR silencing in

ST88-14 MPNST cells (Supplemental Figure 8A), suggesting
that HuR could be responsible for regulating expression of YAP/
TAZ pathway components.
To test this hypothesis, we examined whether HuR associated
with mRNAs encoding key protein components of the YAP/TAZ
pathway by performing RIP followed by reverse transcription and
quantitative PCR analysis (RIP-qPCR) in MPNSTs. To avoid possible confounding effects of cell type heterogeneity in tumor samples, we used MPNST cell lines instead. We found that there was a
jci.org   Volume 130   Number 7   July 2020
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Figure 10. HuR regulates a core transcriptional circuitry in MPNST cells. (A)
GSEA plots showing enrichment of genes upregulated in MPNST cells by JQ1
treatment (fold change >1.5; adjusted P value < 0.05) (13) and shHuR#1-infected ST88-14 MPNST cells. (B) RIP-qPCR analysis showing binding of
HuR to BRD2, BRD3, and BRD4 in 4 MPNST cell lines (ST88-14, 90-8, S462,
STS-26T). Data are normalized to control IgG IPs and are presented as mean
± SEM, 2-tailed unpaired Student’s t test. (C) Representative Western
blots showing a downregulation of BRD proteins after HuR silencing in
ST88-14 MPNST cells. (D) Violin plot showing the distributions of BRD2,
BRD3, and BRD4 ChIP-Seq signal at enriched regions in shCtrl-infected and
shHuR#1-infected ST88-14 MPNST cells. The y axis shows BRD ChIP-Seq
signal in units of reads per million (rpm)/bp. The loss of BRD occupancy at
BRD-enriched regions after HuR silencing is highly significant (BRD2, P =
4.44 × 10–16; BRD3, P = 1.332 × 10–15; BRD4, P = 1.332 × 10–15; Welch’s t test).
(E) Gene regulatory networks among differentially expressed, epigenetically
active TFs that are either direct or indirect targets of BRD proteins. Red and
blue circles represent differentially upregulated and downregulated TFs,
respectively, in shCtrl-infected cells. Light green edges indicate regulatory
interactions unique to shCtrl cells, light blue edges indicate those unique
to shHuR#1-infected cells, and black edges indicate those present in both
phenotypes. Pointed arrows indicate activation, and blunted arrows indicate
inhibition. Functional categories are based on Gene Ontology Biological Processes. (F) GSEA plot showing strong enrichment of epigenetically active TFs
that are either direct or indirect targets of BRD proteins in shCtrl-infected
compared with shHuR#1-infected ST88-14 MPNST cells. (G and H) ToppGene
analysis of HuR-regulated TF network in MPNSTs (red circles from E), as
classified according to pathway categories (G) or disease (H).

strong enrichment of YAP1 mRNA, encoding YAP1, and TEAD1 and
TEAD2 mRNAs, encoding TEAD1 and TEAD2, two transcriptional
partners of YAP1, in HuR RIP samples (Figure 7C). Notably, HuR
depletion led to a striking reduction in the levels of these proteins in
both the NF1-derived ST88-14 cell line (Figure 7D) and the sporadic
cell line STS-26T (Supplemental Figure 8B). Suppressing the YAP/
TAZ pathway by HuR silencing reduced the mRNA levels of downstream YAP/TAZ target genes in both cell lines (Figure 7E and Supplemental Figure 8C). Interestingly, although we did not find that
TAZ or TEAD4 mRNAs were direct targets of HuR, HuR depletion
led to a strong reduction in their expression levels, likely due to an
indirect effect on their transcription, mRNA stability, or translation.
Our results indicate that HuR can regulate expression of key
YAP/TAZ pathway components in MPNST cells, which could lead
to the aberrant elevated HIPPO-TAZ/YAP expression seen in
mouse and human tumor tissue samples and the hyperactivation
of this essential oncogenic pathway for MPNST pathogenesis.
HuR regulates key cell cycle genes in MPNSTs via an RB/E2F axis.
RAS/MEK/ERK and PI3K/AKT/mTOR are 2 other major signaling pathways that are upregulated in MPNSTs and have important
roles in MPNST pathogenesis (1, 2). GSEA analysis revealed that
many components of these pathways were significantly downregulated by HuR silencing, including activation of receptor tyrosine
kinases such as PDGF (Supplemental Figure 9, A and B). Along the
same lines, GSEA also showed a strong positive correlation among
genes regulated by the MEK inhibitor PD0325901 in the MPNST
cell line 90-8TL (13) and genes regulated by HuR silencing in
ST88-14 MPNST cells (Supplemental Figure 9C). In addition, several signatures of downstream effectors of these pathways, including the RB and E2F TFs, were inhibited by HuR silencing (Figure
8, A and B). These effectors are frequently dysregulated in cancer
and play an important role in cell cycle regulation (22).
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To examine the specific function of HuR in controlling these
tumorigenic pathways, we examined whether HuR was bound to
and regulated expression of different components of these pathways (Figure 8C). By RIP-qPCR analysis, we found that HuR was
bound to CCND1, CCND2, CDK2, CDK6, p27, E2F1, E2F2, and
E2F3 mRNAs (Figure 8D). In both the ST88-14 and STS-26T cell
lines, we found that silencing HuR strongly reduced the levels of
several proteins encoded by these mRNAs, accordingly to the role
of HuR in promoting mRNA stability and translation (Figure 8E
and Supplemental Figure 9D). However, in specific cases, HuR
can also inhibit protein translation (16), as described for p27 (37).
Here, similarly, we found that HuR depletion led to an increase
in p27 protein level. p21 protein levels were also increased, not
as a direct target of HuR, but possibly as one of the key proteins
increasing in abundance during cell senescence.
Collectively, our results suggest that HuR may play a direct
role in driving cell cycle progression via E2F TFs in MPNST cells by
acting at several levels: (a) by enhancing the expression of specific
cyclins and CDKs to promote phosphorylation of RB1 to release
E2F TFs, (b) by repressing production of p27, an inhibitor of CDKs,
and (c) by directly regulating the levels of E2F TFs.
HuR activates a key Wnt/β-catenin oncogenic program in
MPNSTs. Using the Sleeping Beauty forward genetic screen,
signaling through the canonical Wnt/β-catenin pathway was
recently identified as a key genetic driver of MPNST tumorigenesis (33, 34). The canonical Wnt pathway is activated after Wnt
stimulation, leading to an inhibition in degradation of β-catenin,
which then enters the nucleus and binds to a member of the lymphoid-enhancing factor 1/T cell factor (LEF1/TCF) family and
other transcriptional cofactors including BCL9 and Pygopus to
regulate the expression of target genes involved in diverse cellular
processes (38). We found that HuR silencing led to a downregulation of MYC, SOX9, and AURKA/B mRNAs (Supplemental Table
4), which have previously been identified as downstream targets
of the Wnt/β-catenin pathway in different cell systems (39–41).
Here, we confirmed that these genes were also downstream target genes in MPNST cells by silencing β-catenin using specific
shRNAs in the ST88-14 and STS-26T cell lines (Supplemental Figure 10, A and B).
In line with this set of targets, GSEA analysis showed that
several signature data sets associated with this pathway were significantly downregulated by HuR silencing (Figure 9, A and B,
and Supplemental Tables 5 and 6). RIP analysis showed that HuR
associated with CTNNB1 mRNA, which encodes β-catenin as well
as BCL9 mRNA, which we also identified as a target of HuR from
our RIP-Chip analyses (Supplemental Table 2 and Figure 9C). A
functional role of β-catenin in controlling MPNST cell growth and
viability had already been shown using shRNA-mediated silencing
of CTNNB1 (34).
HuR silencing led to a notable reduction in the levels of β-catenin and BCL9 in ST88-14 (Figure 9D) and STS-26T cells (Supplemental Figure 10C), showing that HuR controlled protein production from these mRNAs. HuR depletion also significantly lowered
the levels of the key downstream targets, including c-MYC, SOX9,
AURKA, and AURKB, further supporting a role for HuR in regulating Wnt/β-catenin–mediated gene transcription. To confirm
these results, we examined the capacity of ectopically expressing
jci.org   Volume 130   Number 7   July 2020
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a degradation-resistant form of β-catenin to abrogate the effects
of HuR silencing in MPNST cells. We found that constitutive
expression of the β-catenin mutant partially blocked the effects
of HuR silencing on downregulation of the downstream Wnt pathway targets in ST88-14 MPNST cells (Figure 9E). In line with this,
although silencing HuR still reduced ATP levels and cell number
in cells overexpressing the β-catenin mutant, there was a significant recovery of these parameters in comparison with HuR-silenced cells expressing the empty vector plasmid (Figure 9F). Similar results were obtained in the sporadic MPNST STS-26T cell line
(Supplemental Figure 10, D and E).
Conversely, overexpression of BCL9 using a lentiviral vector failed to rescue the suppression of MPNST growth induced
by HuR silencing (data not shown), suggesting that regulation of
BCL9 is not central to the biological consequences elicited by HuR
in MPNST cells. Our results above also show that a number of key
oncogenic TFs, including c-MYC, SOX9, or E2Fs, were downregulated by HuR silencing. Similarly, here, we found no major effect
on MPNST growth when the expression of these TFs was restored
using lentiviral overexpression constructs after HuR silencing
(Supplemental Figures 11 and 12).
These data suggest that there is hierarchical prioritization for
HuR function in MPNSTs: HuR primarily regulates the expression
of key master regulators (e.g., β-catenin, YAP/TAZ), which in turn
control the production of cell cycle proteins and TFs.
HuR regulates a core transcriptional circuitry in MPNST cells by
controlling expression of BRD proteins. Deregulation of the epigenome has also emerged as an important component of the pathogenesis of MPNSTs. In particular, 2 recent studies pointed to a
role of bromodomain and extraterminal domain (BET) proteins
in the activation and maintenance of an aberrant transcriptional
program (13, 32). BET proteins, including bromodomain-containing protein 2 (BRD2), BRD3, and BRD4, bind to hyperacetylated
lysines in promoter/enhancer regions, and subsequently recruit
cofactors to control transcription of oncogenic drivers, such as
MYC and E2F (42).
In MPNST cells, a small-molecule inhibitor of the BET proteins, JQ1, blocks proliferation and can induce apoptosis in MPNST
cells in vitro and in vivo, highlighting the importance of these proteins in MPNST pathogenesis (13, 32). Using GSEA analysis, we
found a striking enrichment of genes activated by JQ1 treatment in
MPNST cells (13), and genes upregulated by HuR silencing in our
data set (Figure 10A). Furthermore, in line with our RIP-Chip analyses, where we found enrichment of BRD2 mRNA in HuR-bound
fractions (Supplemental Table 2), we found that mRNAs encoding
all 3 BET family members, BRD2, BRD3, and BRD4, were highly
enriched in HuR fractions in RIP-qPCR analyses of MPNST cell
lines (Figure 10B). HuR silencing strongly reduced all 3 BET proteins in both the ST88-14 and STS-26T cell lines, suggesting a role
for HuR in promoting the stability and/or translation of the corresponding mRNAs (Figure 10C and Supplemental Figure 13A).
A functional role of BRD4 in controlling cell growth and viability
in MPNST cells had already been shown using shRNA-mediated
silencing (13, 32). Here, we found that silencing BRD2 using 2 distinct BRD2-specific shRNAs also led to a reduction in cell growth
and viability (Supplemental Figure 13, B–D), underscoring the
importance of this transcriptional regulator in MPNSTs.
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Key recent studies have shown that JQ1 treatment in melanoma and multiple myeloma cells depletes BRD2 and BRD4 from
promoter and enhancer regions of the genome, and this was associated with the disruption of transcriptional programs in these
cells (43, 44). To gain mechanistic insight into the role of HuR in
mediating the function of BET proteins in MPNST cells, we investigated changes in BET occupancy on a genome scale by ChIP-Seq
in ST88-14 cells after HuR silencing. We found that HuR silencing significantly reduced genome-wide BRD2, BRD3, and BRD4
occupancy by approximately 60%, approximately 50%, and
approximately 45%, respectively (Figure 10D).
Next, to examine the functional effects of the BETs’ occupancy
on transcriptional regulation, we generated a chromatin landscape
in ST88-14 cells using H3K4me3 to identify promoters, H3K4me1
to identify enhancers, and H3K27ac to identify active promoter/
enhancer regions. Using this information, we performed network
analysis to generate a network of transcriptional regulators that
are targets of BRD proteins and regulated by HuR expression. In
brief, we identified BRD-bound epigenetically active (active promoters and enhancers) and differentially regulated TFs in control
and HuR-silenced cells (Figure 10E). It is apparent from this analysis that there is a considerable number of transcriptional regulators in MPNST cells that are associated with BRD proteins and
that control key processes, such as proliferation. Importantly, we
found that a substantial proportion of these transcriptional regulators were especially sensitive to HuR inhibition, which depleted
BRD proteins from their promoter/enhancer regions and downregulated their expression (Figure 10E, red circles). Thus, GSEA
analysis of BRD-bound transcriptional regulators demonstrated
a significant enrichment of genes activated in control cells and
repressed by HuR silencing (Figure 10F). Gene enrichment analysis by ToppGene suite (45) identified these repressed regulators
as being overrepresented in different oncogenic pathways, including E2F and MYC TF networks, proliferation, and TP53-regulated
pathways, and for different cancers (Figure 10, G and H).
Collectively, these data demonstrate that BRD proteins are
enriched at promoter/enhancer regions of key transcriptional regulators in MPNST cells, and that a reduction in their levels and
genome occupancy by HuR silencing suppresses this oncogenic
transcriptional circuitry.

Discussion

Cancer arises from multiple genetic lesions that lead to aberrant
gene expression programs, which are increasingly being recognized as fundamental for the acquisition, development, and maintenance of cancer phenotypes. Compelling recent evidence shows
that cancer cells can develop absolute dependencies on discrete
molecular regulators — out of the thousands of human proteins
that contribute to control of gene expression — that drive these
dysregulated transcriptional programs. There is nowadays an
intense search for these key regulators through focused mechanistic studies, since they represent attractive targets for effective and
enduring therapies in cancer (9, 10).
In this study, we present evidence that MPNST cells exhibit
an exceptional reliance on the RNA-binding protein HuR for their
abilities to survive, proliferate, and disseminate. HuR inhibition
prevented the formation of tumors in xenograft models, and even
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induced a striking regression of tumor volume in established
tumors. Furthermore, HuR strongly promoted the metastatic
capacity of MPNST cells, one of the worst prognostic features of
this cancer. We propose that HuR-regulated transcriptomes promote the survival and adaptation strategies that allow the disseminated cancer cells to survive in the circulation and migrate
to, extravasate, and thrive in incompatible foreign microenvironments of distant tissues. Consistent with these results, we found
that HuR regulated essential biological capabilities of MPNST
cells, including cell cycle progression and sustained proliferation, resisting cell death in stress conditions and enabling replicative immortality. Notably, the functional consequences of HuR
inhibition were largely comparable in a representative panel of 4
MPNST cell lines obtained from patients with different NF1 status, even though these exhibit heterogeneous cellular growth rates
and alterations in expression of a number of cell cycle proteins
(24). This lack of major differences, functional or mechanistic,
between NF1-derived and sporadic MPNSTs after HuR silencing
supports the view that relatively similar molecular mechanisms
are involved in the pathogenesis of MPNSTs, and that HuR can be
a broad target for MPNSTs, irrespective of NF1 status (1).
Mechanistically, our RIP-Chip and transcriptomics data
showed a global dysregulation of several signaling pathways and
molecular regulators in these cancer cells, including the HIPPO-YAP/TAZ, PI3K/AKT/mTOR, RAS/RAF-MEK-ERK, and Wnt/
β-catenin pathways and bromodomain regulation of gene transcription, while our focused analyses revealed that regulation
by HuR of specific components of these pathways likely led to
the aberrant signaling. Several of these pathways, including
Wnt/β-catenin, seem to be specific to MPNSTs, since we find
that HuR cannot regulate them in normal Schwann cells (data
not shown). We posit that this capacity of HuR to simultaneously control several essential molecular regulators that operate
in these cancer cells explains in large part the striking effects of
HuR inhibition in MPNST cells. All these pathways have been
shown to contribute to MPNST pathogenesis in seminal studies
from several laboratories using various genetically engineered
mouse models or culture systems (1, 2, 6, 13, 32–34, 46). However,
genetic or pharmacological inhibition of these targets individually has, in general, been modestly effective and largely cytostatic.
Instead, concurrent targeting of different pathways has proved
more potent. Thus, combined inhibition of YAP/TAZ and PDGFR
signaling activity (6), BRD proteins and MEK activity (13), or the
mTOR and Wnt/β-catenin pathways (34) is strongly synergistic in
blocking tumor growth, and can even induce apoptosis.
These observations strongly support the view that parallel and
redundant pathways control the oncogenic traits in MPNST cells,
a phenomenon that has been associated with the emergence of
therapeutic resistance in cancer cells (10, 21). This is particularly true for targeted therapies against kinase-mediated signaling
cascades, which are organized in a linear and hierarchical manner, with different receptor tyrosine kinases at the top, activating
a reduced number of kinase signaling cascades, including RAS/
RAF-ERK, PI3K/AKT, and JAK/STAT, that operate in parallel but
that can crosstalk with one another (10). This linear and redundant architecture facilitates bypassing of a signaling pathway after
its inhibition for another, thus blocking the therapeutic effects of
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the drugs. This paradigm is also consistent with the disappointingly poor results obtained in phase I and II clinical trials targeting
individual components of kinase cascades in MPNST patients.
Because of the superior results obtained from additive effects of
cotargeting multiple pathways, current clinical trials are more
focused on combination drug therapy (1, 25). Our results strongly argue that targeting HuR could be equally as effective as the
combined treatments, as we find that HuR inhibition potently
suppresses several of the oncogenic signals in MPNSTs, leading to
profound cytostatic and cytotoxic effects on the growth, as well as
the metastatic capacity, of tumors.
Strikingly, we find that targeting HuR can both prevent the
formation of tumors and metastatic nodules, and lead to shrinkage of fully established tumors and metastases. Thus, therapeutic intervention could be equally effective in newly diagnosed or
recurrent tumors, which has particularly appealing translational
importance, since timing of intervention and stage of disease have
been raised as possible causes of the negative results in clinical
trials in MPNSTs. However, even though our promising data on
pharmacological inhibition of HuR could represent a viable therapy for patients with MPNSTs, it is still unclear whether the preclinical efficacy observed in this study using cell lines and mice can be
translated to the clinic. Whether HuR is a valid therapeutic target
in MPNSTs warrants direct investigation.
Our ChIP-Seq data reveal a large network of transcriptional
regulators operating in MPNST cells that are associated with key
biological functions. Notably, we find that this network is highly
sensitive to levels of HuR, which can regulate expression of key
components of this network via modulation of BRD protein levels
and/or signaling pathways. An essential role for BRD proteins in
regulating gene expression has also been shown in several malignancies, including MPNSTs, and interestingly, we find that HuR
silencing in MPNSTs phenocopies to a large extent treatment
with the BET inhibitor JQ1, at least in terms of gene expression
profiles. In addition, the displacement of BRD proteins on promoter/enhancer regions of active cancer-related genes by JQ1 in
hematological malignancies and melanoma (42–44) is similar to
the reduced promoter/enhancer occupancy on transcriptional regulators in MPNSTs that we found after HuR silencing. Thus, our
data suggest that dysregulation of the transcriptional program in
MPNSTs by HuR silencing could be in large part mediated by the
influence of HuR on the MPNST transcriptional network.
Remarkably, we found that HuR depletion led to strong suppression of MYC and E2F levels that was accompanied by a highly significant reduction in the abundance of MYC- and E2F-transcribed gene sets, pointing to a general suppression of transcription
at E2F- and MYC-driven targets by HuR inhibition. These proto-
oncogenic TFs are among the most important drivers of tumorigenesis, as they regulate cell growth, proliferation, apoptosis, and
metabolic pathways (22, 23), and represent some of the important
targets for cancer therapy, although efforts to directly target these
TFs have proved unsuccessful so far (9). Our work could thus have
far-reaching implications for cancer therapy, since it suggests an
alternative strategy to effectively target these TFs. MYC regulation
also represents one of the best examples of the “multifunctional”
capacity of HuR in driving expression of particular oncoproteins.
MYC levels are regulated by major growth-regulatory and oncojci.org   Volume 130   Number 7   July 2020
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genic signaling pathways, including the Wnt/β-catenin, JAK/STAT,
and Notch pathways that induce MYC transcription and the mTOR
pathway that increases the efficiency of MYC mRNA translation,
together with function of PI3K and RAS signaling and AURKA/B
that increase the stability of MYC protein (22, 47). The striking
downregulation of MYC levels in MPNST cells by HuR inhibition
could potentially be mediated by a combinatorial action at several
of these nodes of regulation, which are themselves under strong
HuR influence. Similarly, E2F levels/function in MPNST cells
could be determined by HuR via its effect on multiple regulatory
mechanisms, including cyclin-CDK expression, RB phosphorylation, and E2F transcription/translation.
RBPs play a central role in regulation of gene expression, and
thus it is not surprising that their dysregulation has been linked
to several human diseases, including neurological disorders and
cancer (48, 49). These dynamic regulators can bind to and regulate thousands of functionally related genes, regulating every
hallmark of cancer cells. Recent detailed studies have shown that
RBPs are rapidly emerging as key oncogenic drivers in a variety of
malignancies (48, 50–53). In this study, we show that the RBP HuR
has pleiotropic functions in MPNSTs, driving tumor growth and
metastasis by, quite strikingly, influencing almost all key signaling
pathways and regulators discovered in MPNSTs so far, including
the PI3K/AKT/mTOR, RAS/RAF-MEK-ERK, Wnt/β-catenin, and
HIPPO-YAP/TAZ pathways, and transcriptional regulators including SOX9, AURKA/B, and BRD proteins, as well as the proto-oncogenic TFs MYC and E2Fs. Over 1500 RBPs have been described,
and several of them are dysregulated in MPNSTs (data not shown).
It would be interesting to examine their biological and mechanistic functions in MPNSTs, and whether they have broad functions
similar to those of HuR or regulate distinct pathways.
This function of HuR in establishing the highly intricate regulatory networks operating in MPNSTs to coordinate multiple
cancer hallmark traits supports a “master” regulatory function
for HuR in MPNSTs. Thus, by elevating HuR levels, MPNST cells
have elaborated an adaptive mechanism to amplify and regulate
key oncogenic signals and modulate transcriptional programs to
confer a competitive advantage to these cancer cells, promoting
MPNST growth and metastatic spread (see Graphical Abstract).

Methods

Cell culture. Human MPNST cell lines S462, STS-26T, ST88-14, and
90-8 and an immortalized normal human Schwann cell line (iHSCλ2)
were obtained from Nancy Ratner (Cincinnati Children’s Hospital Medical Center) (24, 34). Immortalized plexiform neurofibroma–derived
Schwann cells (ipNF SC) were purchased from ATCC (ATCC CRL
3390). The cells were maintained in DMEM (Thermo Fisher Scientific)
supplemented with 10% (vol/vol) FBS (Thermo Fisher Scientific) and
1% (vol/vol) antibiotic/antimycotic (Thermo Fisher Scientific) under
standard conditions of culture in 37°C and 5% CO2.
Human Schwann cells were isolated from the sural nerves of
donors with informed consent (see below). Withdrawn nerves were
stripped of their epineurium, and fascicles were separated from
the remaining interfascicular epineurium. Fascicles were cut into
2-mm-long pieces and incubated in humidified conditions and 10%
CO2 for 7–14 days in DMEM (Gibco) with 10% FBS (MilliporeSigma),
500 U/mL penicillin/streptomycin (Gibco), and 2.5 mg/mL ampho3862
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tericin (Gibco). Fascicles were then digested in DMEM with 10% FBS,
500 U/mL penicillin/streptomycin, 0.8 U/mL dispase grade I (MilliporeSigma), and collagenase type 1A 160 U/mL (MilliporeSigma).
The resulting Schwann cells were then amplified on plates coated with
0.1 mg/mL poly-l-lysine in DMEM with 20% FBS, 100 U/mL penicillin/streptomycin, 0.5 mM forskolin (MilliporeSigma), 2.5 mg/mL
amphotericin, 2.5 mg/mL insulin (MilliporeSigma), 10 nM β1-heregulin (MilliporeSigma), and 0.5 mM IBMX (MilliporeSigma). Amplified
Schwann cells were plated in DMEM with 10% FBS in the absence of
β1-heregulin for at least 24 hours before analysis.
Lentivirus preparation and infection of MPNST cells. Lentiviral particles (Supplemental Table 7) were produced in HEK293FT cells. For
single-infection experiments, MPNST cells were incubated with different lentiviral particles together with 8 μg/mL Polybrene (Merck) for
enhancing infection efficiency. Selection of infected cells was started
48 hours after infection with puromycin (4 μg/mL) for 2 days in supplemented growth medium or with geneticin (G418 sulfate) (Thermo
Fisher Scientific) at 50 μg/mL for 5 days in growth medium without
antibiotic/antimycotic. For the inducible knockdown plasmids, after
infection and selection, cell lines were treated with 0.5 μg/mL doxycycline every 24 hours for 3 days. Infection efficacy was tested by
Western blot and quantitative reverse transcriptase PCR analyses. For
rescue experiments, cells were first infected with control or β-catenin–
overexpressing plasmids and selected with puromycin, and then further infected with shHuR#3 lentiviral particles followed by selection
with geneticin, as above. After infection and selection, MPNST cells
were replated at specific densities for the different functional assays.
All assays were conducted in triplicate, with at least 3 independent
experiments performed for each assay.
Small-molecule HuR inhibitors. For culture studies, MPNST cell
lines were treated with the following small-molecule HuR inhibitors
for 48 hours: (a) MS-444 (29), obtained from Philipp Krastel (Novartis Institutes for Biomedical Research), reconstituted in DMSO and
used at a final concentration of 10 μM; (b) pyrvinium pamoate (MilliporeSigma), reconstituted in DMSO and used at a final concentration
of 2 μM; and (c) tanshinone mimic 6N (TM-6N) (31), obtained from
Alessandro Provenzani (University of Trento), reconstituted in DMSO
and used at a final concentration of 10 μM. 0.1% DMSO was used in
control cultures.
For in vivo xenograft studies, 1 × 106 STS-26T cells mixed in 1:4
PBS/Matrigel were injected subcutaneously in the left and right back
flanks of mice, respectively, under standard procedures and tumors
allowed to grow up to 100 mm3 average volume, as described above.
The mice then received i.p. injections of MS-444 (25 mg/kg) dissolved
in PBS/5% N-methyl pyrrolidine (NMP) (MilliporeSigma) or vehicle
control every 48 hours for a further 10 days.
For lung metastasis studies, 1 × 106 STS-26T cells were injected in
the lateral tail vein of mice and left for 2 weeks to allow basal formation of lung metastases, as described above. The mice then received
i.p. injections of MS-444 (25 mg/kg) dissolved in PBS/5% NMP (MilliporeSigma) or vehicle control every 48 hours for a further 2 weeks.
All the microarray, RNA-Seq, and ChIP-Seq data were deposited
in the NCBI Gene Expression Omnibus database (GEO GSE120687).
Statistics. All analyses were done using Microsoft Excel or
GraphPad Prism 6.00 (www.graphpad.com). Data are shown in dot
plots or histograms as mean ± SEM. A P value of less than 0.05 is
deemed statistically significant. Statistical analysis was performed
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by 2-tailed unpaired Student’s t tests, Mann-Whitney U test, 1-way
ANOVA with post hoc analysis by Tukey’s multiple-comparisons
test, 2-way ANOVA with Tukey’s multiple-comparisons test, or as
indicated. Quantifications were performed from a minimum of 3
experimental groups.
Study approval. For animal studies, xenograft or experimental
lung metastasis experiments were approved by the Biosafety and Welfare Committee (BAWC) at CIC bioGUNE, and carried out following
the ethical guidelines and recommendations from the Association for
Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
For human studies, patient samples were obtained in accordance
with the ethical standards of the institutional and/or national research
committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standard:
(a) Frozen human normal nerves (n = 5), neurofibromas (n = 12),
and MPNSTs (n = 15) were obtained from the Stanmore Musculoskeletal Biobank, a satellite of the University College London (UCL)/
University College London Hospitals (UCLH) Biobank (Human Tissue Authority License 12055), which was approved by the National
Research Ethics Committee (NREC) (reference 15/YH/0311). This
specific study was approved by the NREC-approved UCL/UCLH Biobank Ethical Review Committee (reference EC17.14).
(b) Peripheral nerves for Schwann cell culture were retrieved from
donors after consent under the National Health Service Blood and
Transplant (NHSBT) research study entitled “Collection of peripheral
nerves for control cells for brain tumor treatment research,” NHSBT
study 61. The full research project title was “Identifying and validating
molecular targets in low grade brain tumors” (Research Ethics Committee [REC] number 14/SW/0119; IRAS reference 153351).
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